AFFIMED ANNOUNCES ACCEPTANCE OF AFM24 CLINICAL ABSTRACT AT THE 2024 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

On April 24, 2024 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE), in combination with atezolizumab, Roche’s checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Affimed, APR 24, 2024, View Source [SID1234642305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC)

Presenting Author: Hye Ryun Kim

Poster Session: Developmental Therapeutics—Immunotherapy

Abstract Number: 2522

Poster Presentation Time: Saturday, June 1, 2024, 9:00 a.m. – 12:00 p.m. CDT

The full abstract will become available on ASCO (Free ASCO Whitepaper)’s website on May 23, 2024 at 5:00 p.m. (EDT). More details about the ASCO (Free ASCO Whitepaper) conference are available online at Attend | ASCO (Free ASCO Whitepaper) Annual Meeting.

About AFM24
AFM24 is a tetravalent, bispecific ICE that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.